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Aromatase inhibition is the gold standard for treatment of early and advanced breast cancer in postmenopausal women suffering
from an estrogen receptor-positive disease. The currently established group of anti-aromatase compounds comprises two reversible
aromatase inhibitors (anastrozole and letrozole) and on the other hand, the irreversible aromatase inactivator exemestane. Although
exemestane is the only widely used aromatase inactivator at this stage, physicians very often have to choose between either
anastrozole or letrozole in general practice. These third-generation aromatase inhibitors (letrozole/Femara (Novartis Pharmaceuticals,
Basel, Switzerland) and anastrozole/Arimidex (AstraZeneca, Pharmaceuticals, Macclesfield, Cheshire, UK)), have recently
demonstrated superior efficacy compared with tamoxifen as initial therapy for early breast cancer improving disease-free survival.
However, although anastrozole and letrozole belong to the same pharmacological class of agents (triazoles), an increasing body of
evidence suggests that these aromatase inhibitors are not equipotent when given in the clinically established doses. Preclinical and
clinical evidence indicates distinct pharmacological profiles. Thus, this review focuses on the differences between the non-steroidal
aromatase inhibitors allowing physicians to choose between these compounds based on scientific evidence. Although we are waiting
for the important results of a still ongoing head-to-head comparison in patients with early breast cancer at high risk for relapse
(Femara Anastrozole Clinical Evaluation trial; ‘FACE-trial’), clinicians have to make their choices today. On the basis of available
evidence summarised here and until FACE-data become available, letrozole seems to be the best choice for the majority of breast
cancer patients whenever a non-steroidal aromatase inhibitor has to be chosen in a clinical setting. The background for this
recommendation is discussed in the following chapters.
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Adjuvant endocrine therapy has an important role in postmeno-
pausal women (PMW) with hormone receptor-positive (HRþ)
breast cancer. Efficacy of anti-hormonal treatment of early breast
cancer is based on the fact that estrogens may stimulate the growth
of residual cancer cells or contribute to the initiation of a new
primary cancer over time.
Selective estrogen-receptor (ER) modulators, such as tamoxifen,
have been the gold standard of care for women with HRþ breast
cancer for the last 30 years (Jordan, 2004; Geisler et al, 2008).
Tamoxifen therapy for 5 years can reduce the odds of recurrence
and death by 47 and 26%, respectively (Early Breast Cancer
Trialists’ Collaborative Group, 2005; Howell et al/ATAC Trialists
Group, 2005).
Aromatase inhibitors (AIs) have now replaced tamoxifen as the
standard of care for adjuvant endocrine therapy in the treatment of
PMW with hormone-sensitive breast cancer. Three generations of
AIs have been developed during the last 3 decades. Of these, the
third-generation AIs have more favorable tolerability profiles and
are more selective and/or potent compared with first- and second-
generation agents (Nabholtz et al, 2000; Mouridsen et al, 2001).
There are two broad categories of third-generation AIs (Lønning
and Geisler, 2008). The reversible non-steroidal agents include
anastrozole and letrozole (triazole derivatives). The third agent,
exemestane, is an androstenedione derivative that functions as
an irreversible steroidal inhibitor (or inactivator). The triazole
derivatives bind to the cytochrome P-450 component of the
aromatase enzyme, whereas the steroidal compound exemestane
binds to the substrate-binding pocket of the aromatase enzyme
(Geisler et al, 1998), leading to its degradation (Figure 1). AIs are
now widely used as first-line therapy for PMW with hormone-
sensitive early breast cancer, as first-line therapy for metastatic
disease, and as second-line agents in cases of tamoxifen resistance.
This review emphasises the potency and emerging efficacy
differences between third-generation AIs and places particular
emphasis upon comparisons between anastrozole and letrozole.
DIFFERENCES IN THE MECHANISM AND POTENCY
OF AI-INDUCED ESTROGEN SUPPRESSION
In vitro results
Several studies evaluating the reduction of aromatisation in vitro
have compared the potency of third-generation AIs (Bhatnagar
et al, 2001). Miller (1999) used two ex-vivo assays of aromatase
activity in particular fractions of breast cancer tissue and in
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tively inhibited in both particular fractions of breast cancers and
cultures of mammary adipose tissue fibroblasts. In another study
by Miller et al (2001), immunohistochemical analyses revealed that
treatment with anastrozole or letrozole resulted in significant
decreases in progesterone receptor (PgR) expression, a marker for
estrogen function. Bhatnagar et al (2001) demonstrated that in
rodent cells, normal human adipose fibroblasts, and human cancer
cell lines, letrozole was consistently 10–30 times more potent than
anastrozole in its ability to inhibit intracellular aromatase. It is
important to note, however, that in vitro assays may not accurately
reflect the degree of inhibition produced/achieved in vivo.
Animal models
An intratumoural aromatase model system in mice was developed
to mimic postmenopausal ERþ breast cancer. This animal model
takes into account the importance of locally produced (intra-
tumoural) aromatase, as well as the fact that breast cancer occurs
mainly in PMW. Although these mice (ovariectomised, athymic,
and immunosuppressed nude mice) have no significant peripheral
estrogen production capability and no adrenal androgen produc-
tion, AI efficacy is assessed after inoculation with human
breast carcinoma cells transfected with the human aromatase gene
(MCF-7arom cells) (Brodie et al, 2005). Using this aromatase
xenograft model, letrozole was shown to be more effective than
tamoxifen in suppressing breast tumour growth without causing
endometrial proliferation. Additionally, tumours continuing to
progress on tamoxifen therapy remained sensitive to second-line
therapy with letrozole.
In vivo measurements
The biochemical efficacy of AIs in vivo may be determined from
their effects on total body aromatisation, as well as from changes in
plasma and tissue estrogen levels. Because of their high sensitivity,
tracer methods that allow the calculation of whole-body aromatase
inhibition are preferred (Lønning and Geisler, 2008). Unfortu-
nately, these methods are labor-intensive, and analyses are usually
limited to small numbers of patients. Plasma estrogen measure-
ment is a cruder but simpler method that allows screening of much
larger numbers of patients. As there may be significant variation
between local estrogen synthesis in addition to uptake of estrogens
from the circulation in some tumours, direct measurement of
intratumour estrogens is required to assess the potency of AI
estrogen suppression in malignant target tissues (Lønning and
Geisler, 2008).
The third-generation AIs approved by the Food and Drug
Administration (anastrozole, letrozole, and exemestane) are highly
selective competitive inhibitors/inactivators of the aromatase
enzyme. Although first- and second-generation AIs inhibit
estrogen synthesis in vivo up to 90%, third-generation compounds
reproducibly cause X98% aromatase inhibition in humans
(Geisler et al, 2008). Table 1 provides a comparison of the total
body aromatase inhibition of third-generation AIs compared with
the first- and second-generation compounds. Furthermore,
suppression of plasma levels of estrogens by 490% has been
consistently demonstrated with all third-generation AIs (Dowsett
et al, 1995; Geisler et al, 1996, 1998, 2002, 2008).
Among third-generation AIs, letrozole seems to produce the
most extensive estrogen suppression. Results from an intrapatient
crossover study revealed that letrozole (2.5mg daily) consistently
resulted in more potent aromatase inhibition compared with
1.0mg anastrozole (Geisler et al, 2002). In PMW undergoing
primary treatment for locally advanced ERþ/PgRþ breast
cancer, letrozole suppressed pretreatment tumour levels of
estradiol (E2), estrone (E1), and estrone sulfate (E1S) by 97.6,
90.7, and 90.1%, respectively (Figure 2A) (Geisler et al, 2008). This
level of suppression is superior to that previously reported for
anastrozole using the same methods: 89.0, 83.4, and 72.9%,
respectively (Geisler et al, 2001). Direct comparisons of reanalyzed
samples also found superior suppression of plasma estrogen levels
with letrozole compared with anastrozole (Geisler et al, 2008),
E2 (average suppression by 95.2 vs 92.8%; P¼0.018), E1 (98.8%
suppression vs 96.3%; P¼0.003), and E1S (98.9% suppression vs
95.3%; P¼0.003) (Figure 2B). Recently, Dixon et al (2008)
confirmed that letrozole reduces plasma estrogen levels to a
greater degree than does anastrozole at clinical doses. The results
of these two translational studies, Geisler et al (2008) and Dixon
et al (2008), raise the question of whether differences in potency
translate into differences of clinical importance. Although it has
been postulated by some authors that aromatase inhibition above a
defined level (f. eks. 90% inhibition) might not increase the clinical
efficacy, the lessons we learned from clinical studies through the
last 3 decades suggest that estrogen suppression and clinical
efficacy are tightly correlated also above 90% aromatase inhibition
Exemestane
Non-steroidal aromatase inhibitors
Steroidal aromatase inactivator
O
O
CH2
N
N
N Letrozole
NC CN H3C
Anastrozole
N
N
N
H3C NC CN CH3
CH3
Figure 1 Chemical structures of currently used antiaromatase compounds.
(A) Steroidal aromatase inactivator. (B) Non-steroidal aromatase inhibitors.
Table 1 Inhibition of whole-body aromatisation among three genera-
tions of aromatase inhibitors
Generation Compound Dose (mg) % Inhibition Reference
First Aminoglutethimide 250 qid 90.6 MacNeill et al (1992)
Formestane (IM) 250 2w 84.8 Jones et al (1992)
Second 500 2w 91.9
500 w 92.5
Formestane (po) 125 od 72.3 MacNeill et al (1992)
125 bid 70.0
250 od 57.3
Second Rogletimide 200 bid 50.6 MacNeill et al (1992)
400 bid 63.5
800 bid 73.8
Second Fadrozole 1 bid 82.4 Lønning et al (1991)
2 bid 92.6
Third Anastrozole 1 od 96.7 Geisler et al (1996)
1 od 97.3 Geisler et al (2002)
a
Third Letrozole 2.5 od 498.9 Dowsett et al (1995)
2.5 od 499.1 Geisler et al (2002)
a
Third Exemestane 25 od 97.9 Geisler et al (1998)
Abbreviations: od¼once daily; bid¼twice daily; qid¼four times daily; w¼weekly;
2w¼twice weekly; po¼oral; IM¼intramuscular.
aDetected in a direct, intrapatient
crossover study.
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aminoglutethimide (aromatase inhibition: 90%) and letrozole
(aromatase inhibition: 499%) showing clearly superiority of
letrozole in the setting of advanced breast cancer (Gershanovich
et al, 1998). However, because of the very different side-effect
profiles of aminoglutethimide and letrozole when given in the
clinically established doses, with the latter being much less toxic,
an influence of compliance problems during aminoglutethimide
treatment on the study results cannot be excluded.
It is still a matter of discussion whether differences between
95 and 99% inhibition of aromatisation in vivo translate into
significant different clinical response rates and times. In addition,
although all major phase III trials performed with anastrozole
and letrozole used the same doses of the individual drugs
(1mg anastrozole once daily (o.d.) and 2.5mg letrozole o.d.), it
might be questioned that the optimal clinical dose has been used -
at least for anastrozole. Although a direct intrapatient crossover
trial with anastrozole 1mg o.d. vs 10mg o.d. did not reveal a
significant difference between the two daily doses, it is important
to mention that 8 out of 10 patients experienced a better aromatase
inhibition while on the 10mg o.d. dose (Geisler et al, 1996). In
contrast, the corresponding study comparing letrozole 0.5mg o.d
with 2.5mg o.d. did not reveal a major difference between the two
tested doses (Dowsett et al, 1995). In conclusion, a suboptimal
dosage of anastrozole cannot be totally ruled out. However, this
problem cannot be solved by simply increasing the daily dose of
anastrozole. This would require to repeat all phase III trials with
the higher dose of anastrozole to evaluate clinical responses and
even more important that is, side effects. With patents expiring for
all aromatase inhibitors in a short-time frame, this is probably not
of any interest for the involved pharmaceutical company.
Clinical studies
Neoadjuvant setting. Letrozole is the only AI that has been
demonstrated to possess significantly superior efficacy to
tamoxifen in the neoadjuvant setting, and is the only AI to have
received approval from several countries for use in this setting. In
a randomised, double-blind study in PMW (N¼337) with ERþ
and/or PgRþ breast cancer comparing letrozole with tamoxifen
(Eiermann et al, 2001), letrozole was superior to tamoxifen in
overall objective response rate (55 vs 36%; Po0.001). Furthermore,
breast-conserving surgery (BCS) was possible in more patients
treated with letrozole (45 vs 35%; P¼0.022). In another double-
blind study of PMW with ERþ and/or PgRþ breast cancer
ineligible for BCS, patients were randomly assigned to receive
either 4 months of neoadjuvant letrozole or tamoxifen (Ellis et al,
2001). Letrozole had a significantly better response rate (60 vs 41%;
P¼0.004), and letrozole-treated patients had significantly more
BCS (48 vs 36%; P¼0.036). Differences in response rates were
most marked for patients with human epidermal growth factor
receptor (HER) 1/2þ tumours (88 vs 21%; P¼0.0004).
The Pre-operative ‘Arimidex’ Compared To Tamoxifen Trial was
a randomised, multicenter study comparing anastrozole (n¼228)
with tamoxifen (n¼223) as neoadjuvant treatment in PMW
with HRþ, large, operable breast cancer (Cataliotti et al, 2006).
Objective responses for anastrozole and tamoxifen occurred in
39.5 and 35.4% of patients, respectively (ultrasound), and 50.0 and
46.2% of patients, respectively (caliper). In the intent-to-treat
(ITT) population, surgery became feasible after 3 months of
hormonal therapy in 38.1 vs 29.9% of anastrozole- and tamoxifen-
treated patients, respectively (P¼0.11). In patients receiving
endocrine therapy only (n¼314), surgery became feasible in
43% of patients receiving anastrozole vs 30.8% receiving tamoxifen
after 3 months of treatment (P¼0.04).
In contrast to these findings, the Immediate Preoperative
Anastrozole, Tamoxifen, or Combined With Tamoxifen trial did
not find any significant benefit with anastrozole compared with
tamoxifen. Postmenopausal women with ERþ invasive breast
cancer were randomised to one of three treatment groups:
neoadjuvant anastrozole (n¼113), tamoxifen (n¼108), or anastro-
zole plus tamoxifen (n¼109) (Smith et al, 2005). There were no
significant differences in clinical objective response rates (caliper)
across treatment groups (P¼0.87; anastrozole vs tamoxifen).
The outcome of patients in need of neoadjuvant therapy may
also be altered by the frequency of complete pathological
responses during therapy with an AI. Although complete
pathological responses have been observed in a study published
by Dixon et al, these were not found in the corresponding group of
patients treated with anastrozole (Dixon et al, 1999).
Initial adjuvant setting
Early Breast Cancer
Arimidex, Tamoxifen, Alone or in Combination (ATAC)
trial: This phase III multinational, randomised, double-blind
trial initially comprised 9366 PMW with breast cancer (Baum et al,
2002). It compared anastrozole alone or in combination with
tamoxifen with tamoxifen monotherapy following breast cancer
surgery. Combination therapy was not significantly more bene-
ficial than tamoxifen alone, so the combination arm was
terminated early, leaving further analyses limited to 6241 patients
(Baum et al, 2002). At a median follow-up of 68 months, treatment
with anastrozole in HRþ patients revealed a significant benefit in
disease-free survival (DFS) (hazard ratio (HR)¼0.83; 95%
confidence interval (CI) 0.73–0.94; P¼0.005) and time to
recurrence (TTR) (HR¼0.74; 95% CI: 0.64–0.87; P¼0.0002).
However, there was no significant improvement in time to distant
recurrence (TTDR; HR¼0.84; 95% CI: 0.70–1.00; P¼0.06) or
overall survival (OS; HR¼0.97) in the relevant HRþ patient
population (Howell et al, 2005). At 100 months of follow-up,
investigators observed a significant benefit in TTDR (risk of
distant metastasis (DM)) in HRþ patients receiving anastrozole
(HR¼0.84; 95% CI: 0.72–0.97, P¼0.022). Anastrozole also
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Figure 2 (A and B) Influence of anastrozole (ANA) vs letrozole (LET)
on tissue (A) and plasma (B) estrogen levels: percentage of pretreatment
levels (given as geometric mean) (Geisler et al, 2001, 2008).
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CI: 0.76–0.94; P¼0.003) and TTR (HR¼0.76; 95% CI: 0.67–0.87;
P¼0.0001). Although there were improvements in DFS, there was
still no OS benefit for anastrozole vs tamoxifen (472 vs 477 events,
respectively; HR¼0.97; 95% CI: 0.86–1.11; P¼0.7) (Forbes et al,
2008). The key efficacy endpoints of the ATAC trial across
treatment settings are summarised in Table 2.
Breast International Group (BIG) 1–98 trial: This large
international phase III, randomised, double-blind trial was
independently run by the International Breast Cancer Study Group
(IBCSG), a cooperative academic group interested in an analysis
of letrozole vs tamoxifen in PMW with HRþ breast cancer
(ITT: N¼8010; two-arm option: tamoxifen, n¼911, letrozole,
n¼917; four-arm option: tamoxifen, n¼1548, letrozole, n¼1546,
tamoxifen followed by letrozole, n¼1548, letrozole followed by
tamoxifen, n¼1540) (Thu ¨rlimann et al, 2005). The key efficacy
endpoints across treatment settings are summarised in Table 2.
Initial results (N¼8010) at a median follow-up of 25.8 months
demonstrated the superiority of letrozole over tamoxifen in
prolonging DFS and TTR (but not OS). Letrozole-treated patients
had a significant early benefit in TTDR, with a 27% reduction in
risk for DM at 25.8 months’ median follow up (Thu ¨rlimann et al,
2005). A retrospective study (N¼7707) of BIG 1–98 confirmed
these results; there was a pronounced 30% reduction in early DM
(at 2 years) with letrozole compared with tamoxifen (87 vs 125
events, respectively) (Mauriac et al, 2007). Based on the superiority
of letrozole vs tamoxifen at 25.8 months, the IBCSG decided to
unblind the tamoxifen monotherapy arm only and to allow
patients the choice to crossover to letrozole therapy; 619 (25.2%)
made the informed choice (with counseling) to crossover to the
letrozole arm. As a result of the crossover, in addition to the ITT
analysis, a censored analysis was performed to account for
crossover patients (Mouridsen et al, 2009). Analysis of ITT
patients at a median follow-up of 76 months of letrozole or
tamoxifen monotherapy demonstrated a continued significant
benefit in DFS (HR¼0.88; 95% CI: 0.78–0.99; P¼0.03) and TTDR
(HR¼0.85; 95% CI: 0.72–1.00; P¼0.05) with letrozole (Mouridsen
et al, 2009). There were 40 fewer deaths with letrozole,
demonstrating an emerging survival benefit (303 vs 343; HR¼
0.87; 95% CI: 0.75–1.02; P¼0.08). In the censored analysis,
accounting for patients who crossed-over to letrozole, letrozole-
treated patients had benefit in DFS (HR¼0.84; 95% CI: 0.74–0.99),
TTDR (HR¼0.81; 95% CI: 0.68–0.96), and OS (HR¼0.81; 95% CI:
0.69–0.94). However, the IBCSG concluded that early crossover to
letrozole possibly biased the ITT analysis in favour of tamoxifen
and the censored analysis in favour of letrozole, making accurate
assessments of OS difficult. To adjust for this potential bias, an
additional inverse probability of censoring weighted analysis was
carried out to provide a more accurate estimate of the clinical
benefit of letrozole. The results demonstrated that 5 years of
letrozole significantly improved DFS by 15% (HR¼0.85; 95%
CI: 0.76–0.96) and OS by 17% (HR¼0.83; 95% CI: 0.7–0.97;
Po0.05) (Giobbie-Hurder et al, 2009), reflecting the statistics that
might have been observed in the absence of selective crossover
(Mouridsen et al, 2009). It is important to note that with the
emergence of significantly improved treatments, the issue of
crossover is being addressed in many trials and is not unique
to this trial.
IMPLICATIONS OF CYP2D6 GENOTYPE
The potential effect of CYP2D6 genetic variants on clinical
response in tamoxifen-treated breast cancer patients has recently
gained much interest. CYP2D6 is predominantly responsible for
the 4-hydroxylation of tamoxifen leading to its most active
metabolites, 4-hydroxytamoxifen and endoxifen (Dehal and
Kupfer, 1997). CYP2D6 poor metabolisers have been reported to
be at higher risk for recurrence compared with CYP2D6 wild-type
patients (Schroth et al, 2009). Although the data are still somewhat
conflicting at this point (Dezentje ´ et al, 2009), CYP2D6 genotyping
might become the first predictive factor in breast cancer patients
that may be analysed in a blood sample in the near future. The
reported differences between the tamoxifen arms and the AI-arms
in the large clinical phase III studies in early breast cancer have to
be re-evaluated in the light of these novel findings.
INFLUENCE ON DISTANT METASTASIS
Indirect information from the ATAC and BIG 1–98 trials indicates
that differences in clinical efficacy exist between anastrozole and
letrozole in the initial adjuvant setting. Both AIs improve DFS
compared with tamoxifen in patients with HRþ disease. The most
common type of recurrence seen 2 to 3 years post surgery is DM, a
well-recognised predictor of breast cancer survival (Saphner et al,
1996; Mansell et al, 2009). Only letrozole has been shown to
significantly reduce early DM events (30% reduction in the risk of
DM at 2 years) (Mauriac et al, 2007). A significant reduction in DM
events was also seen with anastrozole in HRþ patients but only at
100 months of follow-up (Forbes et al, 2008). In contrast,
exploratory analysis of the ATAC trial confirmed that most of
the early benefit with anastrozole was not in the prevention of
distant disease; at 2.5 years, there was a 7% benefit in the
prevention of DM (Houghton, 2006).
NOVEL ANTIESTROGENS VS AROMATASE
INHIBITORS
The development of fulvestrant (Faslodex, AstraZeneca,
Pharmaceuticals, Macclesfield, Cheshire, UK), a unique ER
Table 2 Key efficacy endpoints of major clinical trials across treatment settings
ATAC
a BIG 1-98
b
Follow-up
(months) 68 100 25.8 76 76 Censored
c 76 IPCW
c,d
DFS 0.83 (P¼0.005) 0.85 (P¼0.003) 0.81 (P¼0.003) 0.88 (P¼0.03) 0.84 0.85
TTR 0.74 (P¼0.0002) 0.76 (P¼0.0001) 0.72 (Po0.001) NR NR NR
TTDR 0.84 (P¼0.06) 0.84 (P¼0.022) 0.73 (P¼0.001) 0.85 (P¼0.05) 0.81 NR
OS 0.97 (P¼0.7) 0.97 (P¼0.7) 0.86 (P¼0.16) 0.87 (P¼0.08) 0.81 0.83
Reference Howell et al (2005) Forbes et al (2008) Thu ¨rlimann et al (2005) Mouridsen et al (2009) Mouridsen et al (2009) Mouridsen et al (2009)
Abbreviations: ATAC¼arimidex, tamoxifen, alone or in combination; BIG¼breast international group; IPCW¼inverse probability of censoring weighted analysis; NR¼not
reported; DFS¼disease-free survival; TTR¼time to recurrence; TTDR¼time to distant recurrence; OS¼overall survival
aHormone receptor-positive population.
bIntent-to-
treat population.
cFollow-up censored at selective crossover.
dThe weighting adjusts for factors associated with OS and with selective crossover, including baseline factors such as
age, nodal status, tumour grade, and time varying performance status.
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Although experience with fulvestrant in early breast cancer is
limited at this point, recent head-to-head comparisons in the
metastatic setting have revealed that fulvestrant (500mg intra-
muscular (i.m.)/4w) is at least as effective as anastrozole (1mg oral
(p.o.)/o.d.) with significantly improved time to progression for
patients in the fulvestrant arm (Robertson et al, 2009). Thus, the
novel increased dosage of fulvestrant is a promising endocrine
treatment option in all settings of breast cancer, and data for
patients with early breast cancer are awaited in a short-time frame.
THE FEMARA ANASTROZOLE CLINICAL
EVALUATION TRIAL (FACE)
Although the ATAC and BIG 1–98 trials have provided an
extensive data set for anastrozole and letrozole in early breast
cancer, no head-to-head trial of these two AIs has been conducted
in this setting. The ongoing FACE trial was designed to
prospectively address potential efficacy and safety differences
(O’Shaughnessy, 2007). This phase III open-label, randomised,
multicenter study includes node-positive patients randomised to
receive either early adjuvant letrozole or anastrozole. The primary
objective is to compare DFS at 5 years. Secondary objectives are to
assess safety, OS, time to DM, and time to contralateral breast
cancer. The trial was designed to differentiate between the two
drugs in the shortest possible time by enrolling patients at
increased risk of early recurrence of breast cancer, so that the
number of events required to initiate analysis will be obtained
more quickly. The results may help refine treatment strategies for
PMW with breast cancer.
ADVERSE EVENTS (AE) OF AI THERAPY
Because of the extended duration of adjuvant endocrine therapy,
patient tolerability issues and their potential influence on
compliance and therapeutic outcome are important themes. All
in all, third-generation AIs seem to have very similar toxicity
profiles. Most side effects are explained by the general estrogen
deprivation, predictable and similar to those of natural meno-
pause. They may include hot flashes, arthralgia, osteoporosis,
fractures, hypercholesterolemia, and cardiovascular events (see
Table 3 for an overview). Side effects like thromboembolic events
and endometrial cancer that are well established for antiestrogen
therapy, are rarely seen during therapy with aromatase inhibitors.
Although novel antiestrogens like raloxifene are less toxic
compared with tamoxifen when tested head-to-head in women at
increased risk for development of breast cancer, raloxifene has
recently been shown to be less effective in preventing breast
cancer, too (Vogel et al, 2010). Although adverse events of third-
generation AIs have been reviewed extensively in the available
literature (Thu ¨rlimann et al, 2005; Buzdar et al, 2006; Coates
et al, 2007; Coombes et al, 2007), this issue will only be briefly
discussed here.
Lipid metabolism and cardiovascular symptoms
Blood cholesterol was comprehensively and systematically
measured in the BIG 1–98 trial under non-fasting conditions
every 6 months (Thu ¨rlimann et al, 2005). At a mean follow-up of
25.8 months, there was more hypercholesterolemia in the letrozole
arm (43.6, vs 19.2% in the tamoxifen arm), but this AE was
predominantly low grade. Importantly, median changes in
cholesterol levels remained stable at 6, 12, and 24 months (0, 0,
and  1.8%) in the letrozole group but decreased in the tamoxifen
group at each assessment ( 12.0,  13.5, and  14.1%). These
results support a greater lipid-lowering effect of tamoxifen rather
than a detrimental effect of letrozole. Safety analysis at a median of
60.5 months confirmed earlier results. Although there was an
increased lipid impairment vs tamoxifen, hypercholesterolemia
was predominantly of low grade (Thu ¨rlimann et al, 2009).
In contrast, hypercholesterolemia was not a predefined AE in
the ATAC trial; however, results indicated a significantly greater
rate of hypercholesterolemia in the anastrozole arm than in the
tamoxifen arm (9 vs 3%; odds ratio 2.73; Po0.0001) (Buzdar et al,
2006). In conclusion, blood lipids seem to be slightly and equally
increased during therapy with all third-generation AIs (anastro-
zole, letrozole, and exemestane) when compared directly with
tamoxifen, because of the lipid-lowering effects of tamoxifen and
not because of a lipid-increasing effect of AIs.
Musculoskeletal symptoms and bone loss
Up to 30% of all women taking AIs report myalgia or arthralgia. In
the adjuvant setting, the rate of muculoskeletal symptoms is
significantly higher for all third-generation AIs compared with
tamoxifen. These events generally emerge early in treatment, are
low grade and improve with time.
In addition, AIs cause a significant increase in both bone
resorption and formation. Osteoporosis and increased fracture
rates occur in some patients when using AIs (Table 3). Although
preclinical studies suggested that bone loss may be less during
treatment with a steroidal AI (exemestane) compared with non-
steroidal AIs (anastrozole and letrozole), there is no evidence at all
from clinical trials confirming these hypotheses. In contrast, a
randomised trial of healthy volunteers demonstrated that all AIs
have a similar effect on burn turnover (McCloskey et al, 2006).
Because of the early screening for osteopenia and osteoporosis
whenever AIs are implemented in patients with early breast cancer
and liberal use of calcium, vitamin D, and bisphosphonates, the
issue of bone loss seems to be solved for the majority of patients.
Endocrine resistance and future research
Acquired, as well as de novo, resistance to aromatase inhibition
remains a major concern in clinical practice. Future research will
seek to improve our understanding of how to treat AI-resistant
breast cancers and, perhaps more importantly, how to prevent the
onset of AI-induced resistance. Studies in model systems have
suggested that tumour cells gradually adapt to low estrogen levels
during AI-treatment, eventually acquiring resistance. However,
early microarray profiling data suggest extensive heterogeneity in
Table 3 Incidence (%) of third-generation aromatase inhibitor-related
adverse events compared with tamoxifen
Anastrozole Letrozole
Study ATAC BIG 1–98
N 6186 8010
Follow-up (mos) 68 60.5
Arthralgia 35.6 vs 29.4 21.9 vs 16.5
Po0.0001 NR
Osteoporosis NR NR
Fractures 11.0 vs 7.7 7.5 vs 5.7
Po0.0001 NR
Hot flashes 35.7 vs 40.9 35.2 vs 39.5
Po0.0001 NR
Hypercholesterolemia NR 48.7 vs 24.1
NR
Overall cardiac events NR 5.6 vs 5.4
NR
Ischemic cardiovascular disease 4.1 vs 3.4 2.1 vs 1.7
P¼0.1 NR
Reference Howell et al (2005) Thu ¨rlimann et al (2009)
Abbreviations: ATAC¼arimidex, tamoxifen, alone or in combination; BIG¼breast
international group; NR¼not reported; NS¼not significant.
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profoundly suppressed, in vitro models of de novo resistance
suggest that tumour cells may have the capability to develop
estrogen hypersensitivity through changes in gene expression and
regulation of growth factor signalling pathways (Santen et al,
2005). On the basis of these findings, aromatase inhibitors and
anti-HER-2 agents (trastuzumab, lapatinib) have been tested in
combination in clinical studies showing improved progression-free
survival in the combination arms (Johnston et al, 2009; Kaufman
et al, 2009). Interestingly, recent data suggest also a complex
recruitment of nuclear receptor co-activators/-suppressors to the
ER during AI treatment in vivo (Fla ˚geng et al, 2009). Thus,
ER-cofactors have become an area of intense research aiming to
develop novel drugs that may interfere with the ER–cofactor
complexes. Other determinants of endocrine resistance in breast
cancer patients have recently been reviewed by Musgrove and
Sutherland (2009).
The development of novel aromatase antibodies like antibody
677 may provide novel tools for the identification of PMW with
ERþ and aromatase-positive tumours that will respond to AI
therapy before it is initiated (Geisler et al, 2010).
CONCLUSIONS
Aromatase inhibition is now established as standard care in both
early and metastatic breast cancer for HRþ PMW following
crucial phase III trials involving 430000 patients. Highest in-vivo
potency, with superior E2 suppression in human breast cancer
tissue, has been demonstrated with letrozole compared with
anastrozole. In addition to being the most potent non-steroidal AI,
letrozole is the only AI that has demonstrated superior efficacy
in both the neoadjuvant and adjuvant settings compared with
tamoxifen. A significant reduction of early DM in the adjuvant
setting has been shown with letrozole, and a survival benefit is
emerging with longer follow-up in the BIG 1–98 trial. In contrast,
100-month survival data from the ATAC trial do not demonstrate
an OS benefit for anastrozole vs tamoxifen. Third-generation AIs
have a predictable and manageable safety profile, with AEs similar
to symptoms of menopause. The severe AEs associated with
tamoxifen are not observed with AIs. Direct head-to-head
comparisons of AIs are needed to further elucidate differences
among third-generation compounds. Until such data are available,
the clinical data at hand suggest that the third-generation
aromatase inhibitor letrozole may be the best choice when a
non-steroidal AI is indicated.
Finally, whenever tamoxifen is used in clinical trials in the
future, CYP2D6 genotyping should be implemented to further
clarify the role of this potentially predictive marker.
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